SMARTER LEAD OPTIMIZATION
	Cambridge Healthtech Institute , Baltimore, Maryland March 16-17, 2000
	With the application of high-throughput approaches from genomics, combinatorial chemistry, and screening, the pharmaceutical industry is now much more likely to be faced with an overabundance of potential leads, rather than a shortage of initial hits. This shift has placed a premium on enhancements in the ability to quickly select between lead candidates, in ways that result in improved productivity, faster development, and lower costs. Better approaches to the assessment of safety or pharmacokinetic properties are needed to address this bottleneck. In vitro methods and higher throughput assays that allow these tests to be carried out at an earlier stage in the drug development process will be essential. Companies may need to rethink what may represent the best process, rather than simply speed up the rate at which traditional approaches are carried out.
	Organized by:	Cambridge Healthtech Institute
	Deadline for Abstracts:	February 4, 2000
	Registration:	Available on-line
	Email for Requests and Registration:	jlaakso@healthtech.com
	Posted by: Jennifer Laakso   Host: 140.239.39.137 date: November 18, 1999 19:43:56 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.